The Interplay Between Small Vessel Disease and Parkinson Disease Pathology: A Longitudinal Study

Haijia Mao,Yao Zhang,Mingyue Zou,Sangying Lv,Jiajun Zou,Ya'nan Huang,Minming Zhang,Zhenhua Zhao,Peiyu Huang
DOI: https://doi.org/10.1016/j.ejrad.2022.110441
IF: 4.531
2022-01-01
European Journal of Radiology
Abstract:BackgroundCerebral small vessel disease (SVD) related brain changes have been found associated with various clinical symptoms of Parkinson disease (PD). On the other hand, PD pathology and treatment may also accelerate SVD progression.ObjectiveThe aim of this study is to explore the interplay between SVD and PD pathology using longitudinal dataset.MethodsWe screened 66 healthy controls (HCs) and 114 patients from the Parkinson Progression Markers Initiative (PPMI) database. The peak width of skeletonized mean diffusivity (PSMD) was quantified from diffusion tensor images to reflect vascular pathologies at baseline and 24 months follow-up, and dopamine transporter (DAT) imaging data was used to represent the extent of dopaminergic neuronal degeneration at the same point time. We compared the PSMD between PD patients and HCs, and analyzed whether PSMD and DAT availability could predict each other’s progression using multiple regression analyses in PD patients.ResultsPSMD at baseline had no significant difference between the HCs and patients with PD (P = 0.169). Higher baseline PSMD was associated with less DAT reduction in the caudate (β = 0.216, P = 0.029), but not the putamen (β = 0.058, P = 0.552) in PD patients. Baseline caudate and putamen DAT availability had no significant association with PSMD progression (β = -0.006, P = 0.950; β = 0.017, P = 0.860, respectively).ConclusionsMild SVD might slow down PD pathology progression, while the effect of PD pathology on the progression of SVD was not significant.
What problem does this paper attempt to address?